Birol Baytan

Birol Baytan

Auto-generated profile, based on publicly available information

Birol Baytan

Department of Pediatric Hematology, Uludag University, Medical Faculty, Bursa, Turkey

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Pediatric Neurology
Verified
Journal Article
Closed access
BBBirol Baytan
Birol Baytan
MEMelike Sezgin Evim
Melike Sezgin Evim
SGSalih Güler
Salih Güler
AGAdalet Meral Güneş
Adalet Meral Güneş
MOMehmet Okan
Mehmet Okan

1 December 2016 in Turkish Journal of Hematology
Verified
Journal Article
Open access
BBBirol Baytan
Birol Baytan
ÇAÇiğdem Aşut
Çiğdem Aşut
AKArzu Çırpan Kantarcıoğlu
Arzu Çırpan Kantarcıoğlu
MEMelike Sezgin Evim
Melike Sezgin Evim
AGAdalet Meral Güneş
Adalet Meral Güneş
With increasing survival rates in childhood acute lymphocytic leukemia (ALL), the long-term side effects of treatment have become important. Our aim was to investigate health-related quality of life, depression, anxiety, and self-image among ALL survivors. Fifty patients diagnosed with ALL and their siblings were enrolled. The Kovacs Children's Depression Inventory, State-Trait Anxiety Inventory, Offer Self-Image Questionnaire, and Pediatric Quality of Life InventoryTM were used for collecting data. ANOVA tests were used to determine if there were any significant differences between groups. ALL survivors had higher depression, more anxiety symptoms, lower quality of life, and more negative self-image when compared to their siblings. Continuous diagnostic and interventional mental health services might be necessary for possible emotional side effects of treatment during and after the treatment. Rehabilitation and follow-up programs should be implemented for children during and after treatment for ALL.

3 May 2019 in Turkish Journal of Hematology
Verified
Journal Article
Open access
DKDeniz Kızmazoğlu
Deniz Kızmazoğlu
SSSeher Sarı
Seher Sarı
MEMelike Sezgin Evim
Melike Sezgin Evim
AKArzu Çırpan Kantarcıoğlu
Arzu Çırpan Kantarcıoğlu
ÖTÖzlem Tüfekçi
Özlem Tüfekçi
HÖHale Ören
Hale Ören
We investigated the health-related quality of life (HRQL) in survivors of pediatric acute lymphoblastic leukemia (ALL) and evaluated the perceptions of the children, their siblings, and their parents. Seventy ALL survivors, who were between 7 and 17 years of age and had completed therapy ≥2 years, were included. The control group consisted of their healthy siblings. HRQL was assessed by the age-specific KINDLR questionnaire. No significant differences could be found among HRQL scores of ALL survivors with respect to variables such as sex, risk group, and having chronic illness. HRQL scores for physical well-being, emotional well-being, family, and social functioning of the patient and sibling self-reports and parent proxy reports were lower than the expected values for healthy and chronically ill children. These results demonstrate that both ALL survivors and their families need help via psychological counseling programs to improve their HRQL even after completion of therapy.

12 June 2009 in Journal of Child Neurology
Verified
Journal Article
Closed access
ÖÖÖzlem Özdemir
Özlem Özdemir
BBBirol Baytan
Birol Baytan
AGAdalet Meral Gunes
Adalet Meral Gunes
MOMehmet Okan
Mehmet Okan
It has been known for many years that vitamin B12 deficiency can cause neurologic problems. One of these problems is involuntary movements that can appear both before and after the initiation of vitamin B12 treatment. Here, we report 3 infants who developed movement disorder during vitamin B12 administration. The movement disorder consisted of a combination of tremor and myoclonus affecting face, tongue, and limbs. Because of the severity of the symptoms, they all needed symptomatic treatment. In 2 of them, the involuntary movements resolved with clonazepam. The involuntary movements in the other patient were successfully treated with piracetam.

1 January 2020 in Turkish Journal of Hematology
Verified
Journal Article
Open access
TATahir Atik
Tahir Atik
EIEsra Işık
Esra Işık
HOHüseyin Onay
Hüseyin Onay
BABilcag Akgün
Bilcag Akgün
KKKaan Kavaklı
Kaan Kavaklı
FÖFerda Özkınay
Ferda Özkınay
Objective: Hemophilia A (HA) is the most severe X-linked inherited bleeding disorder caused by hemizygous mutations in the factor 8 (F8) gene. The aim of this study is to determine the mutation spectrum of the F8 gene in a large HA cohort from Turkey, and then to establish a phenotype-genotype correlation. Materials and Methods: All HA cases (270 patients) analyzed molecularly in the Ege University Pediatric Genetics Molecular Laboratory between March 2017 and March 2018 were included in this study. To identify intron 22 inversion (Inv22), intron 1 inversion (Inv1), small deletion/insertions, and point mutations, molecular analyses of F8 were performed using a sequential application of molecular techniques. Results: The mutation detection success rate was 95.2%. Positive Inv22 was found in 106 patients (39.3%), Inv1 was found in 4 patients (1.5%), and 106 different disease-causing sequence variants were identified in 137 patients (50.6%). In 10 patients (3.7%), amplification failures involving one or more exonic regions, considered to be large intragenic deletions, were identified. Of 106 different F8 mutations, 36 were novel. The relationship between F8 genotype and inhibitor development was considered significant. Conclusion: A high mutation detection rate was achieved via the broad molecular techniques applied in this study, including 36 novel mutations. With regard to mutation types, mutation distribution and their impact on clinical severity and inhibitor development were found to be similar to those previously reported in other hemophilia population studies.

1 February 2022 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
ÖTÖzlem Tüfekçi
Özlem Tüfekçi
MEMelike Sezgin Evim
Melike Sezgin Evim
AGAdalet Meral Gunes
Adalet Meral Gunes
TCTiraje Celkan
Tiraje Celkan
DKDeniz Yilmaz Karapinar
Deniz Yilmaz Karapinar
HÖHale Ören
Hale Ören
Assestment of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is of utmost importance both for risk classification and tailoring of the therapy. The data of pediatric ALL patients that received treatment with Berlin-Frankfurt-Münster (BFM) protocols were retrospectively collected from 5 university hospitals in Turkey. Of the 1388 patients enrolled in the study 390 were treated according to MRD-based protocols. MRD assestment was with real time quantitative polymerase chain reaction (qPCR) in 283 patients and with multiparametric flow cytometry (MFC)-MRD in 107 patients. MRD monitoring had upstaged a total of 8 patients (2%) from intermediate risk group to high-risk group. Univariate analysis revealed age 10 years or above, prednisone poor response, PCR-MRD ≥10−3 on day 33 and on day 78 as poor prognostic factors affecting event-free survival (EFS). Detection of >10% blasts on day 15 with MFC (MFC-high-risk group) was not shown to affect EFS and/or overall survival (log-rank P=0.339). Multiple logistic regression analysis revealed PCR-MRD ≥10−3 on day 78 as the only poor prognostic factor affecting EFS (odds ratio: 8.03; 95% confidence interval: 2.5-25; P=0.000). It is very important to establish the infrastructure and ensure necessary standardization for both MRD methods for optimal management of children with ALL.